Osteoporosis and its complications

Medical Clinics of North America

Volumn 98, Issue 4, 2014, Pages 817-831

  Varacallo, Matthew A ^a   Fox, Ed J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Bisphosphonates; Fragility fractures; Hip fractures; Osteoporosis; Vertebral compression fractures

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PARATHYROID HORMONE[1-34]; VITAMIN D;

BACKACHE; BONE DENSITOMETRY; BONE DENSITY; COMPRESSION FRACTURE; DAILY LIFE ACTIVITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY DIAGNOSIS; FEMUR FRACTURE; FOLLOW UP; FOREARM; FRAGILITY FRACTURE; FUNCTIONAL STATUS; GOLD STANDARD; HEALTH CARE SYSTEM; HIGH RISK PATIENT; HIP; HIP FRACTURE; HUMAN; HUMERUS; JAW OSTEONECROSIS; METABOLIC BONE DISEASE; OSTEOPOROSIS; OUTPATIENT CARE; PATIENT CARE; PELVIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RADICULOPATHY; REVIEW; RISK ASSESSMENT; SCREENING; SPINE; SPINE FRACTURE; SUPPLEMENTATION; TREATMENT DURATION; UNITED STATES;

BISPHOSPHONATES; FRAGILITY FRACTURES; HIP FRACTURES; OSTEOPOROSIS; VERTEBRAL COMPRESSION FRACTURES;

AGE FACTORS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; COMORBIDITY; DIPHOSPHONATES; ESTROGENS; HIP FRACTURES; HUMANS; OSTEOPOROSIS; RISK FACTORS; SEX FACTORS; SPINAL FRACTURES; VITAMIN D;

EID: 84903711993     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2014.03.007     Document Type: Review

References (54)

1. Bessette L., Ste-Marie L.G., Jean S., et al. Recognizing osteoporosis and its consequences in Quebec (ROCQ): background, rationale, and methods of an anti-fracture patient health-management programme. Contemp Clin Trials 2008, 29:194-211.
2. Bukata S.V., Sieber F.E., Tyler K.W., et al. Aguide to improving the care of patients with fragility fractures. Geriatr Orthop Surg Rehabil 2011, 2:5-39.
3. Varacallo M.A., Fox E.J., Hassenbein S.E., et al. Patients' response toward an automated osteoporosis intervention program. Geriatr Orthop Surg Rehabil 2013, 4(3):89-98.
4. Diab D.L., Watts N.B. Diagnosis and treatment of osteoporosis in older adults. Endocrinol Metab Clin North Am 2013, 42:305-317.
5. Ekman E. The role of the orthopaedic surgeon in minimizing mortality and morbidity associated with fragility fractures. JAm Acad Orthop Surg 2010, 18:278-285.
6. Gedmintas L., Solomon D.H., Kim S.C. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. JBone Miner Res 2013, 28:1729-1737.
7. Johnell O., Kanis J.A., Oden A., et al. Fracture risk following an osteoporotic fracture. Osteoporos Int 2004, 15:175-179.
8. Bogoch E.R., Elliot-Gibson V., Beaton D.E., et al. Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. JBone Joint Surg Am 2006, 88:25-34.
9. Burge R., Dawson-Hughes B., Solomon D.H., et al. Incidence and economic burden of osteoporosis-related fractures in the united states, 2005-2025. JBone Miner Res 2006, 22:465-475.
10. Salkeld G., Cameron I.D., Cumming R.G., et al. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 2000, 320:341-346.
11. Bogoch E.R., Elliot-Gibson V., Wang R.Y., et al. Secondary causes of osteoporosis in fracture patients. JOrthop Trauma 2012, 26:e145-e152.
12. Byszewski A., Lemay G., Molnar F., et al. Closing the osteoporosis care gap in hip fracture patients: an opportunity to decrease recurrent fractures and hospital admissions. JOsteoporos 2011, 2011:404969.
13. Edwards B.J., Bunta A.D., Anderson J., et al. Development of an electronic medical record based intervention to improve medical care of osteoporosis. Osteoporos Int 2012, 23:2489-2498.
14. Harrington T., Lease J. Osteoporosis disease management for fragility fracture patients: new understanding base on three years' experience with an osteoporosis care service. Arthritis Rheum 2007, 57:1502-1506.
15. Khan S.A., de Geus C., Holroyd B., et al. Osteoporosis follow-up after wrist fractures following minor trauma. Arch Intern Med 2001, 161:1309-1312.
16. Leslie W.D., LaBine L., Klassen P., et al. Closing the gap in postfracture care at the population level: a randomized controlled trial. CMAJ 2012, 184:290-296.
17. Marsh D., Akesson K., Beaton D.E., IOF CSA Fracture Working Group, et al. Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 2011, 22:2051-2065.
18. Rozental T.D., Makhni E.C., Day C.S., et al. Improving evaluation and treatment for osteoporosis following distal radial fractures. A prospective randomized intervention. JBone Joint Surg Am 2008, 90:953-961.
19. Sugi M.T., Sheridan K., Lewis L., et al. Active referral intervention following fragility fractures leads to enhanced osteoporosis follow-up care. JOsteoporos 2012, 2012:234381.
20. Vaile J., Sullivan L., Bennett C., et al. First fracture project: addressing the osteoporosis care gap. Intern Med J 2007, 37:717-720.
21. Gosch M., Kammerlander C., Roth T., et al. Surgeons save bones: an algorithm for orthopedic surgeons managing secondary fracture prevention. Arch Orthop Trauma Surg 2013, 133:1101-1108.
22. Miyamoto R.G., Kaplan K.M., Levine B.R., et al. Surgical management of hip fractures: an evidence-based review of the literature. I: femoral neck fractures. JAm Acad Orthop Surg 2008, 16:596-607.
23. Dell R., Green D. Is osteoporosis disease management cost effective?. Curr Osteoporos Rep 2010, 8:49-55.
24. Anonymous Chronic diseases and health promotion 2012, World Health Organization, Geneva, Switzerland, Available at:, Accessed September 1, 2012. http://www.who.int/chp/topics/rheumatic/en/.
25. Cumming R.G., Nevitt M.C., Cummings S.R. Epidemiology of hip fractures. Epidemiol Rev 1997, 19:244-257.
26. Picazo D.R., Villaescusa J.R., Martinez E.P., et al. Late collapse osteoporotic vertebral fracture in an elderly patient with neurological compromise. Eur Spine J 2013, 10.1007/s00586-013-2751-3.
27. Alexandru D., So W. Evaluation and management of vertebral compression fractures. Perm J 2012, 16:46-51.
28. Bayliss M., Miltenburger C., White M., et al. Aconceptual and disease model framework for osteoporotic kyphosis. Osteoporos Int 2013, 24:2423-2432. 10.1007/s00198-013-2317-6.
29. National Osteoporosis Foundation Clinician's guide to prevention and treatment of osteoporosis 2013, National Osteoporosis Foundation, Washington, DC.
30. Menzies I.B., Mendelson D.A., Kates S.L., et al. Prevention and clinical management of hip fractures in patients with dementia. Geriatr Orthop Surg Rehabil 2010, 2:63-72.
31. Brauner D.J., Muir J.C., Sachs G.A. Treating nondementia illnesses in patients with dementia. JAMA 2000, 283:3230-3235.
32. Recker R.R., Hinders S., Davies K.M., et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. JBone Miner Res 1998, 13:168-174.
33. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. NEngl J Med 2000, 342:1478-1483.
34. Block G.A., Raggi P., Bellasi A., et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007, 71:438-441.
35. Russo D., Miranda I., Ruocco C., et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007, 72:1255-1261.
36. Wicherts I.S., van Schoor N.M., Boeke A.J.P., et al. Vitamin D status predicts physical performance and its decline in older persons. JClin Endocrinol Metab 2007, 92:2058-2065.
37. Unnanuntana A., Saleh A., Mensah K.A., et al. Atypical femoral fractures: what do we know about them?. JBone Joint Surg Am 2013, 95:e8.1-e8.13.
38. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996, 348:1535.
39. Greenspan S.L., Schneider D.L., McClung M.R., et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002, 136:742.
40. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637.
41. Bukata S.V., Puzas E. Orthopedic uses of teriparatide. Curr Osteoporos Rep 2010, 8:28-33.
42. Augustine M., Horwitz M.J. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis. Curr Osteoporos Rep 2013, 11:400-406.
43. Hermann A.P., Abrahamsen B. The bisphosphonates: risks and benefits of long term use. Curr Opin Pharmacol 2013, 13:435-439.
44. Woo S.B., Hellstein J.W., Kalmar J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144:753-761.
45. Allison M.B., Markman L., Rosenberg Z., et al. Atypical incomplete femoral fractures in asymptomatic patients on long term bisphosphonate therapy. Bone 2013, 55:113-118.
46. Saleh A., Hegde V.V., Potty A.G., et al. Bisphosphonate therapy and atypical fractures. Orthop Clin North Am 2013, 44:137-151.
47. Tamminen I.S., Yli-Kyyny T., Isaksson H., et al. Incidence and bone biopsy findings of atypical femoral fractures. JBone Miner Metab 2013, 10.1007/s007744-013-0448-7.
48. Dell R.M., Adams A.L., Greene D.F., et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. JBone Miner Res 2012, 27:2544-2550.
49. Honig S., Chang G. Osteoporosis: an update. Bull NYU Hosp Jt Dis 2012, 70:140-144.
50. Schilcher J., Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009, 80:413-415.
51. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NEngl J Med 2007, 356:1809-1822.
52. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. NEngl J Med 2001, 344:333-340.
53. Dell R, Greene D, Tran D. Stopping bisphosphonate treatment decreases the risk of having a second atypical femur fracture. Read at the annual meeting of the American Academy of Orthopaedic Surgeons. San Francisco, February 7-11, 2012. Paper 190.
54. Sale J.E., Gignac Monique A.M., Hawker G., et al. Decision to take osteoporosis medication in patients who have had a fracture and are 'high' risk for future fracture: a qualitative study. BMC Musculoskelet Disord 2011, 12:92.